Aap Implantate Ag · XETR:AAQ1
Aap Implantate — H1 2016 Earnings Presentation
14 slides from Aap Implantate's earnings presentation, Aug 15, 2016
Slide 1: aap Implantate AG Q2/H1 2016 Report Conference Call
aap Implantate AG Q2/H1 2016 Report Conference Call Bruke Seyoum Alemu, CEO Marek Hahn, CFO Berlin, August 15, 2016
Slide 2: Safe Harbor Statement
Safe Harbor Statement Our publication may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual
Slide 3: Implementation of Strategic Imperatives: Progress in Q2/2016
Implementation of Strategic Imperatives Progress in Q2/2016 Products Customers Accelerating Value-based Innovation Enhancing Enhancing Market Market Access Access LOQTEQ®: Notice of allowance received for further US Established countries: Q2/2016Focus on0.7 DACH, Western Europe Services USA: S
Slide 4: Financial Figures Q2/2016
Financial Figures Q2/2016 (in EUR million, sales bridge in KEUR) Sales Q2/2016 Q2/2015 Change Trauma 3.0 3.3 -8% Other 0.4 0.3 +73% Sales continued operation 3.4 3.6 -3% Sales discontinued operation 1.7* 2.9 -43% Group sales 5.1* 6.5 -21% *Includes aap Biomaterials GmbH business from 04/01/2016 to 0
Slide 5: Financial Figures H1/2016
Financial Figures H1/2016 (in EUR million, sales bridge in KEUR) Sales H1/2016 H1/2015 Change Trauma 5.2 6.0 -11% Other 0.7 0.5 +28% Sales continued operation 5.9 6.5 -8% Sales discontinued operation 4.2* 7.1 -41% Group sales 10.1* 13.6 -25% *Includes aap Biomaterials GmbH business from 01/01/2016 t
Slide 6: Divestment of aap Biomaterials GmbH
Divestment of aap Biomaterials GmbH Deconsolidation Profit / Impact Q2/H1 2016 (P & L presentation) EUR million Purchase price for shares 33.0 Liabilities assumed +3.7 Retirement of assets -14.6 Retirement of liabilities +2.8 Selling costs -1.6 Profit share aap Bio -0.1 (01/01 – 05/11/2016) Other +0
Slide 7: Divestment of aap Biomaterials GmbH
Divestment of aap Biomaterials GmbH Deconsolidation Profit / Impact Q2/H1 2016 (Cash Flow presentation) EUR million Purchase price payment received 33.0 Payment for liabilities assumed +3.7 Disposal of cash flow positions -1.4 Paid selling costs -0.8 Cash inflow as at 06/30/2016 34.5 7
Slide 8: Financial Figures Q2/2016
Financial Figures Q2/2016 (EBITDA bridge in KEUR) *Includes aap Biomaterials GmbH business from 04/01/2016 to 05/11/2016 and deconsolidation profit of sale of aap Biomaterials GmbH. 8
Slide 9: Financial Figures H1/2016
Financial Figures H1/2016 (EBITDA bridge in KEUR) *Includes aap Biomaterials GmbH business from 01/01/2016 to 05/11/2016 and deconsolidation profit of sale of aap Biomaterials GmbH. 9
Slide 10: Highlights H1/2016 (Balance Sheet)
Highlights H1/2016 (Balance Sheet) • Sale of aap Biomaterials / Deconsolidation 05/11/2016: Disposal of assets of EUR 14.6 million and debts of EUR 2.8 million Balance sheet changed significantly • Total assets 06/30/2016: EUR 70.0 million (12/31/2015: EUR 54.9 million) +27% Non-current assets
Slide 11: Highlights H1/2016 (Cash Flow)
Highlights H1/2016 (Cash Flow) • Operating Cash Flow H1/2016: EUR -4.1 million (H1/2015: EUR -3.5 million) Net result of EUR 19.4 million in H1/2016 incl. deconsolidation profit of EUR 23.3 million Funds tied up in working capital increase in receivables as quarter-end effect; increase in inve
Slide 12: Outlook FY/2016 and Q3/2016
Outlook FY/2016 and Q3/2016 FY/2016 • Group (continued and discontinued operation): – Completion of aap Biomaterials transaction results in deconsolidation profit of EUR 23.3 million in aap’s consolidated interim financial statements as at 30 June 2016, stated in the discontinued operation – EBITDA
Slide 13: Management Agenda 2016 and beyond
Management Agenda 2016 and beyond Implementation of strategic imperatives Products Customers Accelerating Value-based Innovation Enhancing Enhancing Market Market Access Access LOQTEQ®: Completion of LOQTEQ® portfolio with a Established Established countries: countries: Focus Focus on on DACH,
Slide 14: Many thanks for your attention!
Many thanks for your attention! Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app: 14